IDEAYA Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
IDEAYA Biosciences, Inc. (IDYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2020-03-24
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-12-31 was $400.00K, a 300.00% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-09-30 was $400.00K.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $100.00K.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $0.00.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $2.00M, a 566.67% increase from fiscal 2018.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $300.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $800.00K derived: sum of 2 quarters · filed 2020-03-24 | $2.00M 10-K · filed 2020-03-24 | |
| 2019-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.60M 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $1.20M 10-Q · filed 2019-08-12 | |||
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $100.00K derived: sum of 2 quarters · filed 2020-03-24 | $300.00K 10-K · filed 2020-03-24 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $200.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $200.00K 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |